Velcade is the brand name for bortezomib, a proteasome inhibitor indicated for multiple myeloma and mantle cell lymphoma in specified first-line or relapsed settings. It is administered by intravenous or subcutaneous routes. U.S. initial approval was in 2003.
The FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory multiple myeloma after at least one prior therapy, and accepted a new drug application for iberdomide plus daratumumab and dexamethasone with a PDUFA date of August 17, 2026.
Preclinical and early clinical data show carfilzomib can restore BCMA expression on myeloma cells after CAR T-cell therapy failure, with 6 of 10 patients experiencing renewed clinical responses in a small study.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03829371 |
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT03710603 |
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03234972 |
A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma |
COMPLETED | PHASE3 |
| NCT03217812 |
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) |
COMPLETED | PHASE3 |
| NCT02720510 |
A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) |
TERMINATED | PHASE2 |
| NCT02535806 |
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults |
TERMINATED | PHASE2 |
| NCT02312102 |
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation |
COMPLETED | PHASE1 |
| NCT02195479 |
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma |
COMPLETED | PHASE3 |
| NCT02145715 |
Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma |
UNKNOWN | PHASE1/PHASE2 |
| NCT01998971 |
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma |
COMPLETED | PHASE1 |
